HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Elsibucol inhibits atherosclerosis following arterial injury: multifunctional effects on cholesterol levels, oxidative stress and inflammation.

AbstractBACKGROUND:
Elsibucol is a metabolically stable derivative of probucol with antioxidant, anti-inflammatory and antiproliferative properties. Here we investigated the effect of elsibucol on the development of atherosclerosis following arterial injury in hypercholesterolemic rabbits.
METHODS AND RESULTS:
New Zealand White rabbits were fed a high cholesterol diet that was supplemented or not with 0.5% elsibucol, 1% elsibucol or 1% probucol. An angioplasty of the iliac artery was performed after 3 weeks of diet. We found that treatment with elsibucol significantly decreases blood total cholesterol, LDLc and triglyceride levels. This is associated with a significant 46% reduction of neointimal hyperplasia following arterial injury. Interestingly, the effect of elsibucol on cholesterol levels and neointimal formation appears to be more pronounced than that of probucol. In vitro, elsibucol reduces vascular smooth muscle cell proliferation without affecting cell viability. In vivo, treatment with elsibucol is associated with a significant reduction of cellular proliferation (PCNA immunostaining), oxidative stress (nitrotyrosine immunostaining), VCAM-1 expression and macrophage infiltration in injured arteries. Despite its potent effect on neointimal hyperplasia, elsibucol does not prevent endothelial healing (Evans blue staining) following arterial injury.
CONCLUSIONS:
In hypercholesterolemic animals, elsibucol inhibits atherosclerosis and preserves endothelial healing following arterial injury. The mechanisms involved include lowering of blood cholesterol levels together with a reduction of oxidative stress and inflammation in injured arteries.
AuthorsSylvie Dussault, Wahiba Dhahri, Michel Desjarlais, Raphael Mathieu, Alain Rivard
JournalAtherosclerosis (Atherosclerosis) Vol. 237 Issue 1 Pg. 194-9 (Nov 2014) ISSN: 1879-1484 [Electronic] Ireland
PMID25244503 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2014 Elsevier Ireland Ltd. All rights reserved.
Chemical References
  • Antioxidants
  • Butyrates
  • Cholesterol, LDL
  • Phenols
  • elsibucol
  • Cholesterol
Topics
  • Animals
  • Antioxidants (chemistry)
  • Arteries (pathology)
  • Atherosclerosis (drug therapy)
  • Butyrates (therapeutic use)
  • Carotid Arteries (pathology)
  • Cell Proliferation
  • Cell Survival
  • Cholesterol (blood)
  • Cholesterol, LDL (blood)
  • Endothelium, Vascular (pathology)
  • Hypercholesterolemia (drug therapy)
  • Iliac Artery (pathology)
  • Immunohistochemistry
  • Inflammation (blood)
  • Male
  • Muscle, Smooth, Vascular (cytology)
  • Myocytes, Smooth Muscle (cytology)
  • Neointima (pathology)
  • Oxidative Stress
  • Phenols (therapeutic use)
  • Rabbits
  • Vascular Diseases (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: